Media Hypes Moderna’s COVID Vaccine, Downplays Risks | WHAT REALLY HAPPENED

Media Hypes Moderna’s COVID Vaccine, Downplays Risks

For the second time in a week, news of a “promising” COVID-19 vaccine sent global stock markets on a joy ride and triggered an avalanche of positive news stories which, for the most part, avoided any killjoy questions about vaccine safety or transparency.

On Monday, Moderna announced that its mRNA-1273 COVID vaccine candidate was 94.5% effective, based on interim Phase 3 trial data.

Last week Pfizer announced that analysis of preliminary Phase 3 trial data indicated its BNT162b2 COVID vaccine, developed in partnership with Germany’s BioNTech, was “more than 90% effective.”

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA